Within hospital pharmacy manufacturing suites and licensed aseptic filling lines, L-ornithine L-aspartate is processed as a sterile single-dose parenteral concentrate in annealed glass ampoules or Type I borosilicate vials, with a nominal strength of 5.0 g per 10.0 mL and a corresponding concentration of 0.50 g/mL. The formulation is limited to water for injection, L-ornithine L-aspartate at 50.0% w/v, and sufficient 1 M hydrochloric acid or 1 M sodium hydroxide to achieve a final pH of 6.0–7.0; no preservative is added because the product is packaged as a single-dose container. Release and in-process controls follow USP <1> Injections, Ph. Eur. 5.1.1 Methods of Preparation of Sterile Products, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins with an endotoxin limit below 0.50 EU/mL, USP <788> Method 1 particulate matter limits for small-volume parenterals of ≤6000 particles per container at ≥10 µm and ≤600 particles per container at ≥25 µm, and ICH Q3D elemental impurity permitted daily exposures for parenteral exposure. Compounding is performed at 20–25 °C in 316L stainless steel vessels under a nitrogen overlay to minimize oxidation, followed by sequential filtration through a 0.45 µm prefilter and a 0.22 µm PVDF sterilizing membrane under aseptic conditions. The filtered solution is filled into containers that have been washed and depyrogenated in a tunnel at 250 °C for a minimum residence time of 30 min, and the filled ampoules or vials are terminally moist-heat sterilised at 121 °C for 15 min; if the pH drift during terminal sterilisation exceeds ±0.2 pH units, the process is shifted to aseptic filtration without terminal heat. On high-speed filling lines, the high solute concentration requires fill nozzle bores of at least 2.0 mm and positive shut-off valves to prevent needle clogging and droplet formation at rates above 250 ampoules/min. The terminal finished product types include 10 mL ampoules, 10 mL Type I glass vials with rubber stoppers, and hospital-prepared infusion admixtures diluted in 100–250 mL of 5% glucose solution or 0.9% sodium chloride solution before administration.

Oral Granule Sachets for Hyperammonemia: Granulation Limits and Dissolution Control

The production of single-dose oral granule sachets containing L-ornithine L-aspartate for hyperammonemia uses a wet granulation route because the API dose is high and direct compression is not feasible for sachet filling. A common final fill mass is 5.0 g per sachet with 3.0 g L-ornithine L-aspartate, giving an API load of 60.0% w/w; the remaining 40.0% w/w is composed of mannitol 30.0% w/w, anhydrous citric acid 5.0% w/w, povidone K30 2.0% w/w, colloidal silicon dioxide 0.5% w/w, sodium stearyl fumarate 0.5% w/w, lemon flavour 1.5% w/w, and sucralose 0.5% w/w. The use of citric acid rather than lactose or fructose avoids Maillard reactions between free amino groups in the API and reducing sugars during heated drying; this incompatibility is critical because residual water and warm inlet air can accelerate browning and form Schiff base by-products. Granulation is performed in a high-shear granulator with a 25 L bowl, impeller speed 200–250 rpm, chopper speed 1500 rpm, and purified water addition at 8–12% w/w of the dry mix. The wet mass is discharged through a 4.0 mm sieve and dried in a fluid-bed dryer at inlet air temperature 45–55 °C until residual moisture is ≤2.0% w/w; the dried granulate is sized through a 0.8 mm conical sieve and packed under controlled ≤40% RH into aluminium/PET/PE trilaminate sachets with a heat-seal strength above 30 N/15 mm according to ISO 527-3. In-process limits include loss on drying ≤2.0% w/w, angle of repose ≤35°, and sachet fill weight variation ±5% per Ph. Eur. 2.9.5. If oven drying exceeds 55 °C or the residual moisture drops below 1.0% w/w, the granulate becomes friable and dust generation increases during high-speed vertical form-fill-seal operations; if moisture exceeds 2.5% w/w, clumping and irregular screw feeding occur at filler speeds above 60 sachets/min. Release testing includes identification by liquid chromatography, dissolution according to USP <711> apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid at 37 °C ± 0.5 °C with a Q value established during validation, microbial enumeration per Ph. Eur. 5.1.4, residual solvents according to ICH Q3C, and elemental impurities according to ICH Q3D. The terminal finished product types are 5.0 g single-dose sachets and 3.0 g hospital unit-dose sticks.

What Limits Direct Compression of High-Dose L-Ornithine-L-Aspartate Tablets?

Direct compression of high-dose L-ornithine L-aspartate tablets becomes problematic at drug loads above 55% w/w because the crystalline amino acid salt exhibits brittle fracture under compression; published data specific to L-ornithine L-aspartate compaction is limited, so production-scale decisions rely on instrumented rotary press trials with 8.0 mm or 9.0 mm round concave punches. A representative high-dose core formulation contains 500 mg L-ornithine L-aspartate in a 900 mg core, equivalent to 55.6% w/w, with microcrystalline cellulose PH102 at 28.0% w/w, crospovidone at 8.0% w/w, low-substituted hydroxypropyl cellulose at 4.0% w/w, colloidal silicon dioxide at 3.0% w/w, magnesium stearate at 0.9% w/w, and stearic acid at 0.5% w/w. When direct compression is attempted at compression forces above 18 kN, capping and lamination occur at the tablet cap edge, especially at press speeds above 40 rpm; when compression force is reduced below 12 kN, the tablets fail the acceptance criterion for tablet breaking force measured by USP <1217>, and friability exceeds 1.0% per USP <1216>. The practical processing window therefore uses dry granulation by roller compaction: the pre-blend is compacted on smooth rolls at 30–50 kN roll force and 2.0 mm roll gap, then milled through a 0.8 mm screen, lubricated for 3–5 min, and compressed at 14–16 kN. The film coating step adds 3.0% w/w aqueous hypromellose-based coating at a pan inlet temperature of 60–65 °C and product bed temperature 38–42 °C. In-process tests include weight variation ±5.0%, hardness 80–120 N, friability ≤1.0%, and disintegration time ≤15 min in water at 37 °C ± 2 °C by USP <701>. Release testing follows USP <905> Uniformity of Dosage Units with acceptance value ≤15, dissolution by USP <711> with 900 mL of 0.1 N HCl at 50 rpm, ICH Q3C residual solvents, and ICH Q3D elemental impurities. The finished product types are 500 mg and 1000 mg film-coated tablets packed in PVC/PVDC/aluminium blisters.

In the manufacture of two-piece hard-shell dietary supplement capsules containing L-ornithine L-aspartate for liver health positioning, the filling operation is constrained by the moisture sensitivity of the amino acid salt and by the need to avoid reducing-sugar excipients. A validated fill formulation uses 250 mg L-ornithine L-aspartate in a 600 mg fill mass, equal to 41.7% w/w, with dicalcium phosphate dihydrate at 48.3% w/w, croscarmellose sodium at 5.0% w/w, colloidal silicon dioxide at 2.0% w/w, magnesium stearate at 1.5% w/w, and polyethylene glycol 6000 at 1.0% w/w. The powder blend is prepared in a V-blender at 15 rpm for 20 min, lubricated for 3 min, and filled on an automatic capsule machine with tamping pins at 18–25 °C and ≤45% RH; filling speed is limited to 70,000 capsules/h because higher speeds increase fill weight variation beyond ±5%. Gelatin shells are replaced by hypromellose shells to reduce the risk of shell embrittlement and cross-linking from residual moisture and amino acid salt migration; HPMC shells conform to Ph. Eur. 2.9.1 disintegration requirements and provide a dissolution delay no greater than 10 min in water at 37 °C ± 2 °C. The finished capsules are passed through a metal detector with ferrous, non-ferrous, and stainless steel test cards at 1.5 mm, 2.0 mm, and 2.5 mm sensitivity, respectively, and weighed by an in-line checkweigher. Compliance for the U.S. market follows 21 CFR 111 current good manufacturing practice for dietary supplements, and for the European Union, Directive 2002/46/EC on food supplements applies; many buyers additionally require USP <61> and <62> microbial enumeration, USP <232> and <233> elemental impurity panels, and ICH Q3D risk assessment for oral exposure. The terminal product types are HPMC capsules in size 00 or 000, bottled in HDPE with a desiccant sachet and induction sealed closure.

When Pre-Exercise Ammonia Reduction Is Formulated as a Ready-to-Mix Powder

When formulators position L-ornithine L-aspartate in pre-exercise or intra-exercise ready-to-mix powders, the primary production target is rapid dissolution and dose accuracy in a high-moisture handling environment; however, published data for this specific application is limited, and structure-function claims must be handled under applicable dietary supplement frameworks. A representative single-dose stick pack contains 2.0 g L-ornithine L-aspartate in an 8.0 g fill mass, corresponding to 25.0% w/w, with anhydrous citric acid at 18.0% w/w, sodium bicarbonate at 15.0% w/w, maltodextrin at 28.0% w/w, erythritol at 10.0% w/w, silicon dioxide at 1.5% w/w, sucralose at 0.5% w/w, and flavour at 2.0% w/w; the use of erythritol instead of fructose or glucose prevents Maillard browning during storage at elevated humidity. Dry blending is performed in a ribbon blender at 20 rpm for 15 min, followed by sieving through a 0.5 mm sieve and packaging on vertical form-fill-seal stick pack machines at ≤30% RH with nitrogen purging to keep residual oxygen below 2.0% v/v in the headspace. In-process controls include loss on drying ≤1.5% w/w, fill weight variation ±5%, and seal leakage tested by vacuum decay at −25 kPa for 30 s. The terminal finished product types are ready-to-mix powder sticks, single-dose sachets, and effervescent tablets in tubes; effervescent tablets require additional granulation with a 5.0% w/w lubricant such as sodium benzoate and compression force of 10–14 kN on 25 mm flat-faced tooling. Compliance follows 21 CFR 111 for U.S. dietary supplements and Directive 2002/46/EC in the EU, with finished-product microbial limits tested by USP <61> and <62> and heavy metals tested by USP <232> and <233>; the WADA Prohibited List does not list L-ornithine L-aspartate at the time of writing, but third-party certification standards such as NSF Certified for Sport require batch-level testing for prohibited substances.